Systematic review of the efficacy and safety of nifuratel for patients with lower urinary tract infection


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To investigate the clinical and bacteriological efficacy of nifuratel in the therapy of urinary tract infections. Materials and methods. This systematic review includes all studies published in English and Russian for the period 1969-2020 that assessed the effectiveness of nifuratel in the treatment of lower urinary tract infections (LUTI) in women, including pregnant women. The review was written using the PRISMA checklist. The analysis involved randomized and nonrandomized original clinical trials (prospective controlled, prospective cohort, retrospective studies, etc.) and case series studies that included at least 10patients. Results. After searching for and excluding duplicates, 192 publications were included in the screening, of which 169 ones were excluded by reviewing the title and abstract. A total of 9 studies were obtained for qualitative synthesis, 7 of them were clinical ones that included the analysis of 442patients. Conclusion. The systematic review shows that the efficacy of nifuratel as a drug for the therapy of urinary tract infections is comparable and sometimes superior to that of other antibiotics. Nifuratel shows more pronounced therapeutic efficacy and better tolerability compared to nitrofurantoin. Today, it is impossible to consider LUTI in women in isolation and not take into account the state of biocenosis of the vagina and intestines. Nifuratel is also interesting in that it has a spectrum of activity not only with respect to the main uropathogens, but also the causative agents of individual vaginal infections and is suitable for the treatment of acute and chronic LUTI. However, there remains a need to conduct a large number of randomized controlled trials, as well as to examine the safety profile for renal failure and in the elderly.

全文:

受限制的访问

作者简介

Victoria Kasyan

A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Ph.D., associate professor of the Department of Reproductive Medicine and Surgery

Andrei Zaitsev

A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: zaitcevandrew@mail.ru
Dr. Med. Sci., Professor of the Department of Urology

Tamara Perepanova

N.A. Lopatkin Research Institute of Urology and Interventional Radiology, Branch, National Medical Radiology Research Center, Ministry of Health of Russia

Email: perepanova2003@mail.ru
Dr. Med. Sci., Professor, Head of the Group of Infectious and Inflammatory Diseases and Clinical Pharmacology of the Department of General and Reconstructive Urology

Laura Pivazyan

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: laurapivazyan98@gmail.com
5th year student

Bagrat Grigoryan

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: bagybaga97@gmail.com
5th year student

Yuri Kupriyanov

A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: dr.kupriyanov@gmail.com
Ph.D., assistant to the Department of Urology

Gevorg Kasyan

A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: g.kasyan@outlook.com
Dr. Med. Sci., Professor of the Department of Urology, Head of the Department of Functional Urology

Dmitry Pushkar

A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia

Email: pushkardm@mail.ru
Academician of the Russian Academy of Sciences, Professor, Head of the Department of Urology

参考

  1. European Association of Urology. Guidelines on nrological mnfections. 2019. Available at: www.uroweb.org Accessed 28.08.2020.
  2. Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю., ред. Урология. Российские клинические рекомендации. М.: ГЭОТАР-Медиа; 2016. 496 с.
  3. Ткачук В.Н., Аль-Шукри С.Х., Ткачук И.Н. Эффективность нифуратела при лечении острого неосложненного цистита у женщин. Урологические ведомости. 2018; 8 (Спецвыпуск: Материалы 4-й научно-практической конференции урологов Северо-Западного федерального округа Российской Федерации. 19-20 апреля 2018 г., Санкт-Петербург): 109-10. ISSN 2225-9074.
  4. Albert X., Huertas I., Pereiro 1.1., Sanfelix J., Gosalbes V., Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst. Rev. 2004; 4(3): CD001209. https://dx.doi.org/10.1002/14651858.CD001209.pub2.
  5. Sanchez G.V., Baird A.M., Karlowsky J.A., Master R.N., Bordon J.M. Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients. J. Antimicrob. Chemother. 2014; 69(12): 3259-62. https://dx.doi.org/10.1093/jac/dku282.
  6. Klein R.D., Hultgren S.J. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat. Rev. Microbiol. 2020; 18(4): 211-26. https://dx.doi.org/10.1038/s41579-020-0324-0.
  7. Министерство здравоохранения Р.Ф. Клинические рекомендации. Цистит у женщин. Министерство здравоохранения РФ; 21.05.2021. [Ministry of Health of the Russian Federation. Clinical guidelines. Cystitis in women. Ministry of Health of the Russian Federation. 2021 (21.05.2021). (in Russian)]. Available at: https://cr.minzdrav.gov.ru/schema/14_2#doc_a1
  8. Ikaheimo R., Siitonen A., Heiskanen T., Karkkainen U., Kuosmanen P., Lipponen P., Makela P.H. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin. Infect. Dis. 1996; 22(1): 91-9. https://dx.doi.org/10.1093/clinids/22.L91.
  9. Schwartz D.J., Chen S.L., Hultgren S.J., Seed P.S. Population dynamics and niche distribution of uropathogenetic Escherichia coli during acute and chronic urinary tract infection. Infect. Immun. 2011; 79(10): 4250-9. https://dx.doi.org/10.1128/IAI.05339-11.
  10. Kostin A., Kulchenko N., Yatsenko E. Аntimicrobial therapy of acute uncomplicated cystitis with nifuratel. Archiv Euromedica. 2019; 9(3): 71-3. https://dx.doi.org/10.35630/2199-885x/2019/9/3.22.
  11. Tynan A.P., Macis F.R., Ward-McQuaid J.N. Nifuratel in urinary infections. Br. J. Urol. 1969; 41(3): 271-9. https://dx.doi.org/10.1111/j.1464-410x.1969.tb11883.x.
  12. Поздняк А.Л., Сидорчук С.Н., Молчанов О.Л., Обухова И.Ю. Клиническая и бактериологическая эффективность нифурателя в терапии хронических рецидивирующих циститов, ассоциированных с Ch. trachomatis. Российский вестник акушера-гинеколога. 2017; 17(6): 77. https://dx.doi.org/10.17116/rosakush201717677-82.
  13. Pujari B.R., Macis F.R., Fairley A., Ward-McQuaid J.N. Nifuratel in chronic urinary infections. J. Urol. 1972; 107(1): 112-6. https://dx.doi.org/10.1016/s0022-5347(17)60961-3.
  14. Кульчавеня Е.В., Бреусов А.А. Рецидивирующий цистит и бактериальный вагиноз: как избежать полипрагмазии. Гинекология. 2020; 22(4): 17-21. https://dx.doi.org/10.26442/20795696.2020.4.200275.
  15. McGeachie J., Robinson G., Black D. Antibacterial activity of nifuratel in urine and serum. J. Clin. Pathol. 1972; 25(5): 447-9. https://dx.doi.org/10.1136/jcp.25.5.447.
  16. Hamilton-Miller J.M., Brumfitt W. Comparative in vitro activity of five nitrofurans. Chemotherapy. 1978; 24(3): 161-5. https://dx.doi.org/10.1159/000237776.
  17. Moher D., Liberati A., Tetzlaff J., Altman D.G. ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7): e1000097. https://dx.doi.org/10.1371/journal.pmed1000097.
  18. Higgins J.P.T., Thomas J., Chandler J., Cumpston M., Li T., Page M.J., Welch V.A., eds. Cochrane handbook for systematic reviews of interventions version 6.1. Updated September 2020. Available at: www.training.cochrane.org/handbook.
  19. Sterne J.A.C., Savović J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366: l4898. https://dx.doi.org/10.1136/bmj.l4898
  20. Sterne J.A.C., Hernan M.A., Reeves B.C., Savovic J., Berkman N.D., Viswanathan M. et al. ROBINS-I: a tool for assessing risk of bias in nonrandomized studies of interventions. BMJ. 2016; 355: i4919. https://dx.doi.org/10.1136/bmj.i4919.
  21. Sterne J.A.C., Hernán M.A., Reeves B.C., Savović J., Berkman N.D., Viswanathan M. et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016; 355: i4919. https://dx.doi.org/10.1136/bmj.i4919.21.
  22. National Heart, Lung and Blood Institute. Study Quality Assessment Tools. Available at: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools22.
  23. Davies B.I., Mummery R.V., Brumfitt W. Ampicillin, carbenicillin indanyl ester, and nifuratel in the treatment of urinary infection in domiciliary practice. Br. J. Urol. 1975; 47(3): 335-41. https://dx.doi.org/10.1111/j.1464-410x.1975.tb03978.x.23.
  24. Кладенский Й., Пацик Д., Чермак А. Нифурател, таблетки, в лечении острой неосложненной инфекции мочевыводящих путей. Чешская урология. 1998: 5: 8-10.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021
##common.cookie##